StageBio

StageBio is a prominent international provider of Good Laboratory Practice (GLP)-compliant research, preclinical, and clinical services, specializing in histology, pathology, and specimen archiving. The company caters to a diverse clientele, including the biopharmaceutical, medical device, and contract research industries. StageBio was established through the strategic merger of several respected entities: Histo-Scientific Research Laboratories (HSRL), Vet Path Services, Inc. (VPS), Tox Path Specialists (TPS), and Alizée Pathology. This consolidation of expertise and resources has positioned StageBio as a leading source for high-quality histopathology services within the research and development market. The company further expanded its global footprint and capabilities with the acquisition of TPL Path Labs in Freiburg, Germany, enhancing its ability to serve researchers across North America and Europe.

The integrated service offering from StageBio is comprehensive, encompassing tissue analysis, efficacy determination for new compounds and devices, and toxicological evaluation of products requiring regulatory approval. The company provides detailed pathology reporting for GLP studies, specialized medical device pathology, advanced immunohistochemistry, and in-depth neuropathology services. With a dedicated team of over 30 board-certified veterinary pathologists and more than 100 skilled laboratory technicians, StageBio upholds a strong commitment to scientific integrity, quality, and client satisfaction. Operating from multiple state-of-the-art facilities in the United States and a key laboratory in Europe, the company continues to invest significantly in its technological infrastructure and facilities to meet the escalating global demand for specialized histopathology services, supporting every stage of development from discovery to clinical trials.